Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Compact case
Case
-
Reference no. UVA-E-0456
Published by: Darden Business Publishing
Originally published in: 2020
Version: 3 November 2020

Abstract

This is part of a case series. In early March 2020, Amy Mathers, a physician and faculty member at the University of Virginia Health System (UVA Health), contemplated how UVA Health could get access to COVID-19 testing - and fast. The first patients with COVID-19 symptoms had arrived at the UVA hospital that week, but hospital staff had no ability to confirm the cases. Waiting seven days for a commercial result meant wasting precious isolation rooms and gear if the patient was in fact negative for the novel coronavirus. Should the leadership at UVA Health wait and hope to access the backlogged tests from the Centers for Disease Control and Prevention (CDC), or immediately start sourcing and developing their own? How would they get approval from the Food and Drug Administration (FDA)? Could they access the reagents and equipment they needed to make a reliable test? Many obstacles lay ahead. The A case details the decision, and this B case introduces new decisions about access to testing. Both have been taught online successfully at Darden.

About

Abstract

This is part of a case series. In early March 2020, Amy Mathers, a physician and faculty member at the University of Virginia Health System (UVA Health), contemplated how UVA Health could get access to COVID-19 testing - and fast. The first patients with COVID-19 symptoms had arrived at the UVA hospital that week, but hospital staff had no ability to confirm the cases. Waiting seven days for a commercial result meant wasting precious isolation rooms and gear if the patient was in fact negative for the novel coronavirus. Should the leadership at UVA Health wait and hope to access the backlogged tests from the Centers for Disease Control and Prevention (CDC), or immediately start sourcing and developing their own? How would they get approval from the Food and Drug Administration (FDA)? Could they access the reagents and equipment they needed to make a reliable test? Many obstacles lay ahead. The A case details the decision, and this B case introduces new decisions about access to testing. Both have been taught online successfully at Darden.

Related